Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Macrophage-mediated anti-tumor immunity against high-risk neuroblastoma

7 May 2022

Abstract excerpt

Neuroblastoma is the most common extracranial childhood solid tumor. The majority of high-risk neuroblastoma is resistant/refractory to the current high intensity therapy. Neuroblastoma lacks classical HLA Class I expression and exhibits low mutation burden, allowing neuroblastoma cells to evade CD8+ T cell-mediated immunity. Neuroblastoma cells do not express PD-L1, and tumor-associated macrophages are the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Hypoxia, and Metabolism
Share to Immune cells in cancer
Share to Neuroblastoma Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35525858
DOI: 10.1038/s41435-022-00172-w

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Macrophage-mediated anti-tumor immunity against high-risk neuroblastomaPMID 35525858Read ↗

Clinical Relevance of CD4 Cytotoxic T Cells in High-Risk NeuroblastomaSemantic proximity Read ↗

"Re-educating" Tumor Associated Macrophages as a Novel Immunotherapy Strategy for Neuroblastoma.Semantic proximity Read ↗

The neuroblastoma tumor microenvironment: From an in-depth characterization towards novel therapiesSemantic proximity Read ↗

Neuroblastoma: A Tough Nut to Crack.Semantic proximity Read ↗

Tumor Microenvironment in Neuroblastoma and Immunotherapeutic Approaches: Towards More Effective TreatmentSemantic proximity Read ↗

MYCN Drives a Tumor Immunosuppressive Environment Which Impacts Survival in NeuroblastomaSemantic proximity Read ↗

Exploring and Targeting the Tumor Immune Microenvironment of NeuroblastomaSemantic proximity Read ↗

Exploration of the molecular characteristics of the tumor–immune interaction and the development of an individualized immune prognostic signature for neuroblastomaSemantic proximity Read ↗

Neuroblastoma: Molecular Pathogenesis and TherapySemantic proximity Read ↗

The Neuroblastoma Microenvironment, Heterogeneity and Immunotherapeutic ApproachesSemantic proximity Read ↗

Immunotherapy of Neuroblastoma: Facts and HopesSemantic proximity Read ↗

Blocking MIF secretion enhances CAR T-cell efficacy against neuroblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.